flanders.bio provides you with insights in the vibrant life sciences sector

 

News from flanders.bio and its members

Bone Therapeutics strengthens Board with the appointment of Jean Stéphenne as Chairman

The bone cell therapy company addressing high unmet medical needs in orthopaedics and bone diseases, today announces that Jean Stéphenne has been appointed Chairman of the Board of Directors with immediate effect, replacing Steve Swinson who has informed the Board of his intention to step down.

People | 20 February 18
Read more
20
Feb
2018

Eerstesteenlegging UGent-VIB Onderzoeksgebouw FSVM II

Philippe Muyters, Vlaams minister van Werk, Economie, Innovatie en Sport heeft vanmiddag de eerste steen gelegd van het nieuwe onderzoeksgebouw dat VIB en de UGent bouwen op het Tech Lane Ghent Science Park in Zwijnaarde. Het UGent-VIB Onderzoeksgebouw FSVM II, genoemd naar de Gentse biotechpioniers Fiers, Schell en Van Montagu, zal fysiek verbonden worden met het huidige VIB-UGent Onderzoeksgebouw FSVM I. Alle VIB-UGent onderzoeksgroepen zullen zo gehuisvest worden op één site temidden van de Life Sciences cluster.

20
Feb
2018

Confo Therapeutics is awarded a EUR 1M grant to increase its screening capabilities

Confo Therapeutics announced today that it has received a €1 million grant from the Flemish Government through Flanders Innovation & entrepreneurship (VLAIO). The grant will be used to support the development of new methods for screening libraries of small molecules for the discovery of new therapeutic candidates targeting G-protein coupled receptors (GPCRs), using the company’s proprietary conformation-sensitive single domain antibodies or Confobodies.

20
Feb
2018

CMAST nominated for Trends Gazellen 2018 (East Flanders), for the 3rd time in a row!

CMAST has been nominated - for the 3rd time in a row - as Trends Gazellen for the Province of East Flanders.

19
Feb
2018

Galapagos and MorphoSys present results from Phase 1 study with MOR106

Galapagos NV (Euronext & NASDAQ: GLPG) and MorphoSys AG (FSE: MOR; Prime Standard Segment, TecDAX; OTC: MPSYY) announced the presentation of more detailed results of the Phase 1 study with the investigational IL-17C antibody MOR106 in AD patients at the American Academy of Dermatology (AAD) Annual Meeting 2018 in San Diego, CA, USA, held from 16-20 February. Initial study data were reported in September 2017. In the study, MOR106 showed first signs of activity and durable responses and was generally well tolerated in AD patients.

20
Feb
2018

Eerstesteenlegging UGent-VIB Onderzoeksgebouw FSVM II

Philippe Muyters, Vlaams minister van Werk, Economie, Innovatie en Sport heeft vanmiddag de eerste steen gelegd van het nieuwe onderzoeksgebouw dat VIB en de UGent bouwen op het Tech Lane Ghent Science Park in Zwijnaarde. Het UGent-VIB Onderzoeksgebouw FSVM II, genoemd naar de Gentse biotechpioniers Fiers, Schell en Van Montagu, zal fysiek verbonden worden met het huidige VIB-UGent Onderzoeksgebouw FSVM I. Alle VIB-UGent onderzoeksgroepen zullen zo gehuisvest worden op één site temidden van de Life Sciences cluster.

20
Feb
2018

Confo Therapeutics is awarded a EUR 1M grant to increase its screening capabilities

Confo Therapeutics announced today that it has received a €1 million grant from the Flemish Government through Flanders Innovation & entrepreneurship (VLAIO). The grant will be used to support the development of new methods for screening libraries of small molecules for the discovery of new therapeutic candidates targeting G-protein coupled receptors (GPCRs), using the company’s proprietary conformation-sensitive single domain antibodies or Confobodies.

20
Feb
2018

CMAST nominated for Trends Gazellen 2018 (East Flanders), for the 3rd time in a row!

CMAST has been nominated - for the 3rd time in a row - as Trends Gazellen for the Province of East Flanders.

19
Feb
2018

Galapagos and MorphoSys present results from Phase 1 study with MOR106

Galapagos NV (Euronext & NASDAQ: GLPG) and MorphoSys AG (FSE: MOR; Prime Standard Segment, TecDAX; OTC: MPSYY) announced the presentation of more detailed results of the Phase 1 study with the investigational IL-17C antibody MOR106 in AD patients at the American Academy of Dermatology (AAD) Annual Meeting 2018 in San Diego, CA, USA, held from 16-20 February. Initial study data were reported in September 2017. In the study, MOR106 showed first signs of activity and durable responses and was generally well tolerated in AD patients.

Facts & Figures

CONSULT OUR LIFE SCIENCE DATABASE

 

Innovation is at the core of the life sciences sector and Belgium has a track record of developing ingenious ways to improve the quality of life of millions of people worldwide.

 

Not only extensive life sciences facilities support this high-level technology industry but also financial benefits for R&D companies, international collaborations that guarantee regular cash flow, world known educational systems, a promising product pipeline, and Belgium’s unique central location in Europe.

 

Belgium concentrates on a small territory (30,528 km2) more than 300 life sciences companies with biotech activities. In total, the life sciences sector employs more than 30,000 people (low bound estimation that does not take into account indirect employment generated by the sector). The majority of the companies is related to healthcare, but Belgium also has a strong representation of agricultural and industrial biotech companies.

 

The growing life sciences sector gathers 8 main Belgian universities, 19 research parks and 23 incubators, research institutes, academic hospitals, and clinical research organizations. Biotech companies have access to more than 500,000 square feet of highly flexible infrastructure.

 

Additional assets of Belgium includes: a supportive regulatory and political environment, a highly qualified and productive workforce, a competitive tax environment especially for research companies, a prominent location and an excellent logistical and business infrastructure.

Z Life Sciences

A look behind the scenes of the vibrant life sciences sector in Flanders, Belgium in 11 episodes.

1

VIB

VIB is a life sciences research institute based in Flanders. With more than 1470 scientists from over 60 countries, they perform basic research into the molecular foundations of life and they translate this research into pharmaceutical, agricultural and industrial applications.

2

imec

imec performs world-leading research in nano-electronics and creates groundbreaking innovation in application domains such as healthcare, smart cities and mobility, logistics and manufacturing, and energy. The combination of their widely acclaimed leadership in microchip technology and profound software and ICT expertise is what makes imec unique.

3

Bio Base Europe Pilot Plant

Bio Base Europe Pilot Plant is an independent, state-of-the-art facility that operates from a laboratory level to a multi-ton scale. Bio Base Europe Pilot Plant provides process development, scale-up and custom manufacturing of biobased products and processes. 

 

Interested in a regular update of the Life Sciences and biotech sector in Flanders?